Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company ’s Investigational Pneumococcal Conjugate Vaccine for Adults

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019 1 Broad Phase 3 clinical program for V116 in vaccine-naïve and vaccine-experienced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials